Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Metabolic heat

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    7 result(s) found for: Metabolic heat. Displaying page 1 of 1.
    EudraCT Number: 2017-004527-67 Sponsor Protocol Number: DT-DP-DFU-CR-04 Start Date*: 2018-08-06
    Sponsor Name:DermaTools Biotech GmbH
    Full Title: A Randomised Dose Finding Study Comparing The Safety And Efficacy Of three blinded doses of Diperoxochloric Acid (DPOCl, DermaPro®) and A Standard Moist Wound Dressing In Patients With Non-Healing...
    Medical condition: Diabetic foot ulcer with mean diameter between 1.5 and 4 cm after débridement if indicated), Wound stage Wagner grade I or II, Armstrong stadium A or C (for Wagner-Armstrong-Classification), tr...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) EE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-005841-19 Sponsor Protocol Number: DT-DP-D3 Start Date*: 2013-10-10
    Sponsor Name:DermaTools Biotech GmbH
    Full Title: A Multicentric, Double Blind, randomised, Comparative Phase III Study of the Efficacy of the new Wound Healing Solution Diperoxochloric acid (DPOCL, DermaPro®) compared to isotonic Sodium Chloride ...
    Medical condition: Diabetic foot ulcers with mean diameter between 1.5 and 5 cm after débridement (if indicated); wound stage Wagner grade I or II, Armstrong stadium A or C (for Wagner-Armstrong-Classification), trea...
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004858 10012664 Diabetic foot ulcer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) LV (Completed) LT (Completed) HU (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000099-27 Sponsor Protocol Number: HEAT01 Start Date*: 2017-04-26
    Sponsor Name:The Department of Urology
    Full Title: Toxicity of first-line abiraterone versus enzalutamide in men with metastatic castration-resistant prostate cancer: A randomized clinical trial
    Medical condition: Metastisc castration resistant prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2012-003205-10 Sponsor Protocol Number: 12072 Start Date*: 2012-09-17
    Sponsor Name:University of Nottingham
    Full Title: A randomised placebo controlled trial of follow on Rifaximin for the prevention of relapse of Clostridium difficile associated diarrhoea.
    Medical condition: C.Difficile antibiotic-associated diarrhoeal infection
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-020437-12 Sponsor Protocol Number: DT-DP-D2b Start Date*: Information not available in EudraCT
    Sponsor Name:DermaTools Biotech GmbH
    Full Title: A multicentric, double blind, randomized, comparative Phase II b study of the efficacy of a wound healing solution in patients with diabetic foot ulcer
    Medical condition: diabetic foot ulcer
    Disease: Version SOC Term Classification Code Term Level
    12.1 10012664 Diabetic foot ulcer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) LV (Prematurely Ended) LT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-003326-23 Sponsor Protocol Number: DT-DP-DFU-CR-05 Start Date*: 2021-07-05
    Sponsor Name:DermaTools Biotech GmbH
    Full Title: A Prospective, Randomized, Double-Blind, Vehicle-Controlled Study To Evaluate The Safety and Efficacy of Diperoxochloric Acid (DPOCl, DermaPro®) In Patients With Non-Healing Diabetic Foot Ulcers
    Medical condition: 3. Diabetic foot ulcer treated unsuccessfully for at least 4 weeks with mean diameter between 1.5 and 4 cm after débridement
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) LV (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-005281-30 Sponsor Protocol Number: DUR001-306 Start Date*: 2016-11-03
    Sponsor Name:Allergan Ltd.
    Full Title: A Phase 3, Multicenter, Open-Label, Randomized, Comparator Controlled Trial of the Safety and Efficacy of Dalbavancin versus Active Comparator in Pediatric Subjects with Acute Bacterial Skin and Sk...
    Medical condition: Acute bacterial skin and skin structure infection. For Cohort 5 (from birth to less than 3 months) also patients with sepsis are allowed.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10066412 Staphylococcus aureus skin infection LLT
    20.0 10021881 - Infections and infestations 10037633 Pyoderma (skin infection) LLT
    20.1 10021881 - Infections and infestations 10040873 Skin infection aggravated LLT
    20.0 10021881 - Infections and infestations 10040872 Skin infection PT
    20.0 10021881 - Infections and infestations 10040875 Skin infection pyogenic LLT
    20.0 10021881 - Infections and infestations 10040874 Skin infection NOS LLT
    20.1 10021881 - Infections and infestations 10066409 Staphylococcal skin infection PT
    20.0 10021881 - Infections and infestations 10040047 Sepsis PT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: LV (Prematurely Ended) LT (Prematurely Ended) ES (Prematurely Ended) BG (Completed) GR (Completed) PL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 23 09:09:33 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA